| 臺北醫學大學 |
2014 |
Lemierre syndrome with cervical spondylodiscitis and epidural abscess associated with direct injection of heroin into the jugular vein
|
Lin, Hsin-Ying;Liao, Kuo-Hsing;Jean, Shio-Shin;Ou, Tsong-Yih;Chen, Fu-Lun;Lee, Wen-Sen |
| 臺北醫學大學 |
2014 |
Lemierre syndrome with cervical spondylodiscitis and epidural abscess associated with direct injection of heroin into the jugular vein
|
Lin, Hsin-Ying;Liao, Kuo-Hsing;Jean, Shio-Shin;Ou, Tsong-Yih;Chen, Fu-Lun;Lee, Wen-Sen |
| 臺北醫學大學 |
2008 |
Lemierre's Syndrome --- case report
|
張簡仕煌; 袁聖博; 邱康瑄; 賴銘堂 |
| 臺大學術典藏 |
2020-12-18T08:36:46Z |
Lemierre's syndrome: A forgotten and re-emerging infection
|
PO-REN HSUEH; Hsieh S.-M.; Chen F.-L.; Jean S.-S.; Lee W.-S. |
| 臺大學術典藏 |
2020 |
Lemierre's syndrome: A forgotten and re-emerging infection
|
Lee W.-S.; Jean S.-S.; Chen F.-L.; SZU-MIN HSIEH; Hsueh P.-R. |
| 淡江大學 |
2004-01 |
Lemma Approach in a Time scales
|
錢傳仁; Chyan, Chuan-jen |
| 國立中山大學 |
2004 |
Lemnalia cervicorni, Dendronephthya gigantea及 Nephthea armata三種軟珊瑚活性成分之研究(I)
|
杜昌益; Chang-Yih Duh |
| 國立中山大學 |
2006 |
Lemnalia cervicorni、Dendronephthya gigantea 及Nephthea armata三種軟珊瑚活性成分之研究(III)
|
杜昌益 |
| 國立中山大學 |
2009-03-22 |
Lemnalol, a natural marine compound obtained from the Formosan soft coral Lemnalia cervicorni attenuates nociceptive responses and activity of the spinal glial cells in neuropathic rats
|
Y.C. Lin;S.Y. Huang;C.Y. Duh;Y.H. Jean;W.F. Chen;Z.H. Wen |
| 國立臺灣海洋大學 |
2012-01-01 |
Lemon ascorbate peroxidase: cDNA cloning and biochemical characterization
|
Ya-Han Dai;Chich-Yu Huang;Lisa Wen;Dey-Chyi Sheu;Chi-Tsai Lin |
| 國立臺灣海洋大學 |
2013 |
Lemon protein disulfide isomerase: cDNA cloning and biochemical characterization
|
Yu-Ting Chen;Lisa Wen;Kuo-Chuan Ho;Rong-Huay Juang;Chi-Tsai Lin |
| 臺大學術典藏 |
2020-01-06T03:09:14Z |
Lemon protein disulfide isomerase: cDNA cloning and biochemical characterization
|
Chen, Y.-T.; Wen, L.; Ho, K.-C.; Juang, R.-H.; Lin, C.-T.; KUO-CHUAN HO |
| 朝陽科技大學 |
2006 |
Lempel-Ziv資料壓縮方法之抗錯研究
|
曾顯文 |
| 中國醫藥大學 |
2014-07-17 |
LEM避免UVA誘導的氧化傷害及促進皮膚細胞增生和遷移之機制探討
|
蔡喻丞;Yu-Cheng Tsai |
| 國立臺灣大學 |
2016 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
Shao, Y-Y.; Chen, B-B.; Lin, Z-Z.; Hsu, C-H.; Wang, M-J.; Cheng, A-L.; Hsu, C.; 邵幼雲; 林宗哲; 鄭安理; 陳邦斌; 徐志宏; 許駿 |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
YU-YUN SHAO; Chen B.-B.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2022-08-19T00:20:40Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
CHIUN HSU; Wang M.-J.; Cheng A.-L.; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H. |
| 臺大學術典藏 |
2018-09-10T18:05:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y.-Y.;Chen, B.-B.;Ou, D.-L.;Lin, Z.-Z.;Hsu, C.-H.;Wang, M.-J.;Cheng, A.-L.;Hsu, C.; BANG-BIN CHEN; ANN-LII CHENG |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Yu-Yun Shao;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; YU-YUN SHAO; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Chiun Hsu; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-28T07:25:13Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Chih-Hung Hsu;Wang M.-J.;Cheng A.-L.;Hsu C.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; CHIH-HUNG HSU; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Bang-Bin Chen;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; Shao Y.-Y.; BANG-BIN CHEN; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2021-08-11T03:46:38Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2022-06-10T06:10:59Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
